Endo Looks To Join Genzyme-Impax Renagel Battle

Law360, New York (September 3, 2009, 3:52 PM EDT) -- Endo Pharmaceuticals Inc. has asked a court for permission to intervene in Genzyme Corp.'s Renagel patent infringement case against Impax Laboratories Inc., arguing that Impax challenged a second patent's validity solely in a bid to force first-filer Endo to forfeit its exclusivity period.

In its motion filed Wednesday in the U.S. District Court for the District of Maryland, Endo seeks permission to intervene in order to support Genzyme's motion to dismiss for lack of subject matter jurisdiction Impax's bid to have U.S. Patent Number 6,733,780 declared...
To view the full article, register now.